Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 문지용 | - |
dc.date.accessioned | 2019-12-09T16:44:27Z | - |
dc.date.available | 2019-12-09T16:44:27Z | - |
dc.date.issued | 2018-10 | - |
dc.identifier.citation | EXPERT REVIEW OF PROTEOMICS, v. 15, no. 11, page. 923-935 | en_US |
dc.identifier.issn | 1478-9450 | - |
dc.identifier.issn | 1744-8387 | - |
dc.identifier.uri | https://www.tandfonline.com/doi/full/10.1080/14789450.2018.1539670 | - |
dc.identifier.uri | https://repository.hanyang.ac.kr/handle/20.500.11754/120236 | - |
dc.description.abstract | Introduction: Chronic obstructive pulmonary disease (COPD) is a heterogeneous set of disorders, characterized by airflow limitation, and reduced lung function. Despite increasing knowledge regarding its pathophysiology, there has been limited advancement in therapeutics and the current treatment strategy is symptom management and prevention of exacerbations.Areas covered: Biomarkers represent important tools for the implementation of precision medicine. As fundamental molecules of all living processes, proteins could provide crucial information about how genes interact with the environment. Proteomics studies could act as important tools in identifying reliable biomarkers to enable a more precise therapeutic approach. In this review, we will explore the most promising blood and sputum protein biomarkers in COPD that have been consistently reported in the literature.Expert commentary: Given the complexity of COPD, no single protein biomarker has been able to improve the outcomes of COPD patients. According to preliminary studies, precision medicine in COPD will likely require a combination of different proteins in a biomarker panel for clinical translation. With advancements in current mass spectrometry techniques, an enhancement in the identification of new biomarkers will be observed, and improvements in sequence database search can fill in potential gaps between biomarker discovery and patient care. | en_US |
dc.description.sponsorship | DDS holds a Tier 1 Canada Research Chair in COPD and the De Lazzari Family Chair at HLI. DDS has received research funding from AstraZeneca (AZ), Boehringer Ingelheim (BI), Merck and have received honoraria for sitting on advisory boards of AZ, BI, Regeneron, Sanofi-Aventis and Novartis and for speaking engagements from AZ, BI, and Novartis. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. | en_US |
dc.language.iso | en_US | en_US |
dc.publisher | TAYLOR & FRANCIS LTD | en_US |
dc.subject | COPD | en_US |
dc.subject | sputum biomarker | en_US |
dc.subject | blood biomarker | en_US |
dc.title | Blood and sputum protein biomarkers for chronic obstructive pulmonary disease (COPD) | en_US |
dc.type | Article | en_US |
dc.relation.no | 11 | - |
dc.relation.volume | 15 | - |
dc.identifier.doi | 10.1080/14789450.2018.1539670 | - |
dc.relation.page | 923-935 | - |
dc.relation.journal | EXPERT REVIEW OF PROTEOMICS | - |
dc.contributor.googleauthor | Moon, Ji-Yong | - |
dc.contributor.googleauthor | Leitao Filho, Fernando Sergio | - |
dc.contributor.googleauthor | Shahangian, Kimeya | - |
dc.contributor.googleauthor | Takiguchi, Hiroto | - |
dc.contributor.googleauthor | Sin, Don D. | - |
dc.relation.code | 2018004161 | - |
dc.sector.campus | S | - |
dc.sector.daehak | COLLEGE OF MEDICINE[S] | - |
dc.sector.department | DEPARTMENT OF MEDICINE | - |
dc.identifier.pid | moonji | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.